Contradiction Alert: Navigating LOTIS-7's Regulatory Path and ADCETRIS Market Impact in Recent Earnings Call

Revenue and Financial Performance:
- ADC Therapeutics reported net product revenues of $18.1 million in Q2 2025 and $35.5 million in the first half of 2025.
- The revenues were slightly higher compared to the same periods in the prior year.
- This growth was due to consistent execution on commercial strategies and ongoing clinical trial progress.

Clinical Trial Advancements:
- The LOTIS-7 trial showed promising data with an overall response rate of 93.3% and a complete response rate of 86.7% for ZYNLONTA plus glofitamab.
- The LOTIS-5 trial is expected to reach the prespecified number of PFS events by the end of 2025.
- These advancements are attributed to the potential of ZYNLONTA in combination with other agents to demonstrate superior efficacy and safety profiles.

Operating Expenses and Restructuring:
- ADC Therapeutics reported total operating expenses of $47.8 million on a non-GAAP basis, an 8% increase over the prior year.
- The increase was primarily due to higher R&D costs related to LOTIS-5, LOTIS-7, and PSMA IND-enabling activities.
- The company incurred $13.1 million in restructuring and impairment costs, including the shutdown of its U.K. facility, to reduce operating expenses.

Cash Runway and Financial Strategy:
- ADC Therapeutics completed a $100 million private placement, extending its cash runway into 2028.
- This financial strategy allows the company to fund ongoing R&D efforts and clinical trials.
- The extended runway supports multiple upcoming catalysts, including regulatory approvals and potential commercial expansions.